A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors
Status:
Completed
Trial end date:
2018-11-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the mass balance (that is, cumulative excretion of
total radioactivity [TRA] in urine and feces) and to characterize the pharmacokinetics (PK)
of pevonedistat in whole blood, plasma, and urine, and of TRA in plasma and whole blood
following a single 1-hour infusion of 25 milligram per square meter (mg/m^2)
[14C]-pevonedistat intravenous (IV) solution containing approximately 60 to 85 microcurie
(mCi) (approximately 2.22-3.145 megabecquerel [MBq]) of TRA in participants with advanced
solid tumors in Part A.